Drugs / UI-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07605962 | May 2026 → Mar 2030 expected | cancer of unknown primary site | United Immunity, co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-04 | United Immunity, co., Ltd. | Regulatory United Immunity Announces FDA Clearance of IND Application for UI-102, a TLR7/8 Agonist Encapsulated in a Pullulan Nanoparticle for the Treatment of Solid Tumors unitedimmunity.co.jp ↗ |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UI-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07605962 ↗ |
| Action | Activate | “a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle” NCT07605962 ↗ |
| Route | Intravenous | “UI-102 monotherapy administered intravenously.” NCT07605962 ↗ |
| Target | TLR7 | “a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle” NCT07605962 ↗ |